| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
72,009 |
66,030 |
$4.69M |
| J0178 |
Injection, aflibercept, 1 mg |
4,620 |
3,214 |
$3.22M |
| J2778 |
Injection, ranibizumab, 0.1 mg |
6,615 |
4,710 |
$3.12M |
| J9035 |
Injection, bevacizumab, 10 mg |
12,544 |
10,155 |
$2.55M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
32,656 |
25,384 |
$1.62M |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
12,715 |
12,160 |
$1.43M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
29,798 |
26,380 |
$1.39M |
| 92134 |
|
62,244 |
57,209 |
$1.32M |
| 92250 |
|
34,515 |
31,140 |
$854K |
| 92015 |
Determination of refractive state |
46,307 |
42,482 |
$843K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,157 |
16,714 |
$824K |
| 92235 |
|
9,770 |
9,125 |
$596K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
5,171 |
4,924 |
$537K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,833 |
6,283 |
$496K |
| 92287 |
|
5,579 |
5,179 |
$449K |
| 92201 |
|
29,349 |
26,847 |
$431K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,184 |
5,539 |
$365K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
668 |
416 |
$331K |
| 92083 |
|
9,477 |
8,553 |
$257K |
| 92226 |
|
19,727 |
11,856 |
$255K |
| 92133 |
|
10,020 |
9,063 |
$171K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
511 |
453 |
$103K |
| 92202 |
|
12,304 |
10,998 |
$91K |
| 92020 |
|
7,159 |
6,434 |
$83K |
| 92225 |
|
3,519 |
1,924 |
$60K |
| 68761 |
|
1,190 |
684 |
$48K |
| 92136 |
|
1,730 |
1,593 |
$35K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
133 |
106 |
$34K |
| 92499 |
|
616 |
547 |
$23K |
| 76519 |
|
861 |
736 |
$20K |
| 92002 |
|
284 |
281 |
$19K |
| 76512 |
|
913 |
755 |
$17K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
73 |
73 |
$15K |
| 76514 |
|
1,607 |
1,477 |
$12K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
366 |
341 |
$10K |
| 92060 |
|
105 |
102 |
$7K |
| 67210 |
|
17 |
16 |
$6K |
| 65855 |
|
103 |
80 |
$6K |
| 92273 |
|
31 |
28 |
$2K |
| 92286 |
|
288 |
264 |
$2K |
| 66821 |
|
26 |
16 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
834 |
775 |
$1K |
| 92132 |
|
58 |
54 |
$1K |
| 92285 |
|
359 |
323 |
$1K |
| 92025 |
|
34 |
28 |
$909.23 |
| 83037 |
|
1,027 |
896 |
$830.64 |
| 76513 |
|
16 |
16 |
$717.98 |
| J7999 |
Compounded drug, not otherwise classified |
126 |
62 |
$148.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
12 |
12 |
$122.79 |
| 99024 |
|
3,968 |
2,811 |
$20.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
16 |
12 |
$10.71 |
| G8397 |
Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy |
2,697 |
2,491 |
$5.92 |
| 5010F |
|
2,687 |
2,480 |
$4.13 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
10,798 |
10,260 |
$1.00 |
| 4177F |
|
3,687 |
3,548 |
$0.00 |
| 1036F |
|
842 |
802 |
$0.00 |
| 3285F |
|
755 |
730 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
187 |
170 |
$0.00 |
| 3284F |
|
840 |
812 |
$0.00 |
| 3072F |
|
187 |
183 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
355 |
348 |
$0.00 |
| G8952 |
Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given |
549 |
532 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
96 |
96 |
$0.00 |
| 2019F |
|
228 |
212 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
13 |
13 |
$0.00 |
| G8428 |
Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given |
14 |
13 |
$0.00 |
| G9974 |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity |
3,440 |
3,319 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
12,226 |
11,620 |
$0.00 |
| 2027F |
|
1,007 |
975 |
$0.00 |
| 2022F |
|
2,863 |
2,669 |
$0.00 |
| 0517F |
|
1,406 |
1,359 |
$0.00 |
| 2021F |
|
156 |
144 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
304 |
298 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
31 |
31 |
$0.00 |
| 2026F |
|
58 |
58 |
$0.00 |